Sonoran Biosciences is a privately held early stage pharmaceutical company that has developed SB Gel, the first viscous sustained release carrier. SB Gel enables sustained release of a wide variety of pharmaceuticals to new sites in the body, including joints, device surfaces, and healing tissues. We develop new formulations using approved active ingredients, requiring reduced development cost and risk via the 505(b)(2) approval pathway while retaining the exclusivity of a typical pharmaceutical. Formulations based on SB Gel have potential in a number of indications including deep infection, pain management, and wound healing. Our first product, SB Gel with tobramycin, is being developed for treatment of prosthetic joint infection in a one-stage surgical approach.
Sonoran Biosciences | 1475 N.
Scottsdale Rd. Suite 200 | Scottsdale,
AZ 85257 | P: 480-389-6413
© 2016 Sonoran Biosciences, Inc.